Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (original)   Polyclonal antibody anti-UBE4A/Ufd2b.

2. (original)   Antibody according to claim 1, characterized by being specific for the human and murine UBE4A protein antigen in the portion relative to the sequence of the epitope at the 10- 27 position.

3. (currently amended)   Antibody according to claim 2,_characterized in that said sequence, corresponding to amino acids 10 to 27 in the sequence of the human and murine UBE4A protein is composed as follows: Ile-Ser-Ser-Asn-Pro-Phe-Ala-Ala-Leu-Phe-Gly-Ser-Leu-Ala-Asp-Ala-Lys-Gln.

4. (original)   Antibody according to claim 3, characterized in that it is conjugated with bovine serum albumine (BSA) as a carrier protein.

5. (currently amended)   Immunohistochemical method to determine UBE4A/Ufd2b protein antigen using the antibody according to ~~one or more of claims 1-4~~ claim 1.

6. (currently amended)   Diagnostic and prognostic method to determine molecular abnormalities in the region 11q23 characterized in that it includes a step wherein the antibody according to ~~one or more of claims 1-4~~ claim 1 ~~selettively~~ selectively reacts with the UBE4A/Ufd2b protein antigen.

7. (original)   Method according to claim 6, characterized in that said molecular alterations are consequent to tumours: Neuroblastoma, Acute Lymphoid Leukaemia, Acute Myeloid Leukaemia.

8. (original) Method to evidence any misregulation of the UBE4A/Ufd2b expression in samples of neoplastic human tissues affected by neurodegenerative diseases using Immunohistochemistry.

9. (currently amended) Diagnostic and prognostic kit to be used as a marker of the alterations of the region 11q23, characterized in that it includes the antibody according to ~~one or more of previous claims~~ claim 1.